BSEResult23h ago · 12 Aug 2026, 05:54 pm
Approved unaudited financial results ( Standalone and Consolidated) of the company for quarter ended 30 June 2026
Suraksha Diagnostic Ltd · 544293
✦ AI SummaryResults
Suraksha Diagnostic Ltd has approved unaudited financial results for the quarter ended 30 June 2026, with the results being made available on the company's website. The board also approved the appointment of Mr. Dinesh Gupta as the Chief Financial Officer, and fixed the record date for the purpose of determining the entitlement of shareholders to receive dividend for the financial year ended 31 March 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Suraksha Diagnostic Ltd - 544293 - Results -Financial Results For Quarter Ended 30 June 2026
Attachments (1)
📄pdf
Download →
113759d9-38cf-4ac2-96e6-7518a75434f3.pdf
View document text
Date: 12 August, 2026
The Secretary The Secretary
BSE Limited The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block
Dalal Street Bandra -Kurla Complex, Bandra (East)
Mumbai - 400 001 Mumbai- 400 051
Scrip Code: 544293 Scrip Symbol : SURAKSHA
Dear Sir / Ma’am,
Sub: Outcome of the Board meeting held today i.e. Wednesday, 12 August, 2026
Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (Listing Regulations’) as amended from time to time
Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 33 of the SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) as amended
from time to time, we wish to inform you that the Board of Directors of the Company, at its meeting
held today, i.e. on Wednesday, 12 August, 2026, inter alia, considered and approved/ noted the
following:
1. Approved the unaudited financial results (standalone and consolidated) of the Company for the
quarter ended 30 June, 2026 and the same is enclosed along with the Limited Review Report issued
by the Statutory Auditors of the Company, pursuant to Regulation 33 of SEBI Listing Regulations
marked as “Annexure-A”;
2. Based on the recommendation of the Nomination and Remuneration Committee and the Audit
Committee, appointment of Mr. Dinesh Gupta as the Chief Financial Officer of the Company with
effect from 24 August 2026, who will also act as a Group Chief Financial Officer of the Company
The details as required under Schedule III - Para A (7) of Part A of Regulation 30 of the SEBI Listing
Regulations read with SEBI Master Circular dated January 30, 2026 is marked as “Annexure-B”;
3. Approved the revised Notice convening the 21st Annual General Meeting of the Company for the
financial year 2025-26, to be held on Tuesday, 22 September 2026 through video conferencing/
other audio-visual means (‘VC/OAVM’).
4. Fixed Tuesday, 15 September 2026, as the Record Date, for the purpose of determining the
entitlement of the shareholders to receive dividend for the financial year ended 31 March 2026.
The dividend, if approved by the shareholders at the 21st AGM, shall be paid within the statutory
period prescribed under the Companies Act, 2013.
Suraksha Diagnostic Limited
(Formerly known as Suraksha Diagnostic Private Limited)
CIN: L85110WB2005PLC102265
Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New
Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I Website: www.surakshanet.com
Phone:(033) 6605 9750
The aforesaid financial results are also being made available on the Company’s website at
www.surakshanet.com.
Please note that the meeting commenced at 03:00 P.M. (IST) and concluded at 04:30 P.M. (IST).
You are requested to take the same on record.
Thanking you.
For Suraksha Diagnostic Limited
Ritu Mittal
Joint Managing Director & CEO
DIN: 00165886
Encl.: as above
Suraksha Diagnostic Limited
(Formerly known as Suraksha Diagnostic Private Limited)
CIN: L85110WB2005PLC102265
Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New
Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I Website: www.surakshanet.com
Phone:(033) 6605 9750
Annexure A
MSKA & Associates LLP l 1n 3f ti hn it Fy leB re , n Pc lh om tN. o*, . U Gn -1it ,8I 3 L0 o2 .l.EP 8GP
(Formerty known as M S K A & Associates) xolk ta, w6t 8.ng.l 700 091
Chartered Accountants
lndependent Auditor's Review Report on un.udited standalone ltnancial results of Suraksh.
Diagnostic Limited for the quarter ended June 30, 2025 puBuant to tll€ Re8ulation 33 of
the sEBl (Listin8 06ligatiorE and Dis.losure Requirements) Regulitions, 2015, as amended.
To the 8o.rd of Director: of Sur.khi Di.gnGtic Limited
1 We ha\€ reviewed the accompanying statement of unaudited standatone financiat resutts of
Suralsha oiagnostic Limited (hereinafter referred toas'the Compaoy')for the quarter ended
June 30, 2026 ('the Statement') attached herewith, being submitted by the Company
pursuant to the requirements of Regutation 33 of the se.urities and Exchange Board ot lndia
(Listing Obtigations and Di$tosure Requirements) Regutations, 2015, as amended (the
Regutation:').
2. This statemenr, which is rhe responsibitity of the company's lvlanagement and has been
approved by the Company's Board of Directors, has been prepared in accorclan e with the
recognition and measurement principLe! laid down in lndian Accounting Standard 34 'lnterim
Finao.iat Reporting', prescribed under Section 133 of til€ Companies Act, 2013 ('the Act')
read with relevant rules issued thereunder {'lnd AS 34') and other recognised accounting
principte! generatty a.cepted in lndia and is in €omptian e with the Regulations. Our
responsibility is to express a conctusion on the Statement based on our review.
3. We condEted our review of the Statement in accordance Mth the Standard on Review
EngaSements (sRE) 2410, "Review of lnterim FinanciaL lnformation Performed by the
lndepefldeflt Auditor ofthe Entity'issu€d by the lnstjtute of Chart€red accouotants of lndia.
A review of interim financia( information consists of making inquiries, primariLy of persons
responsibte for finan ial and accounting matters, and apptying anat),ticat and other review
procedures. A review is sub*antiaLLy leis in xope than an audit conducted in accordance
with standardson Auditing sp€cified mder section 143(10) of the Act and consequentty does
mt enable us to obtain assuranae that we would become aware of att significant matters
that might be identified in an audjt. A.cordingly, viE do not express an audit opinion.
Based on our review conducted as stated in paragraph 3 above, nothjng has come to our
attention that causes usto betieve that the accompanying Statement prepared in accordarre
with rh€ recognition and measuremefit prirriples Laid &)wn in lnd AS 34 a nd other r€cognised
accountjng principles generalty accepted in lndia has not disclosed the information required
to be dirlosed in terms of the Regulations, iflctuding the manner in which it is to be
dis.tosed, or that it.ontains any material mjsstatement.
For M S K a & Associates LLP (Formerly known.s M 5 X A & A5sociat6)
Chartered Accountants
ICAIF tion No.105047W/W101187
embeBhiD No.: 061682
uon: %0(. 1682}TDN UY 8 S 03
(olkata
Placer
Date: 12 August 2026
n.silbrcd oflr.e 6ar, R h?j. Tibiu4 w6tdn E qa Hitmy! (tr€.8m (tudr, Nmb3i ,1606r, lkhartnra, ri6,
,,h Fn:bd I adEJn toEri*It' t€Lhd | tui'nb,lfp lcs l6rry.m rtlrd6.b.d I r..ni bbal lrmsl.Erzh
Suraksha
Clinic & Diagnostics
surakshi Dl.Snortic Ltmtted
Reg,stered Oltice : Plot no, DG-12/1, A.rion Area lD, Premiser rc, O2-0t27, Ne Town, RajarlEt, &tkata 7@156, Wet 86gal, tndra
(ClN : 185110W82005P1C102265)
Website I ww.surakshaft t..om
Statement ol u..udlted itandalone fin.n.i.l rerulrr lor the quarter ended !0 June 2026
lO June 2026
I Rqenw tom ole6tion3 8,408.62 7,855.59 1,021.94 10,067.91
156 4r 110.28 109.57 475.71
4,565.03 7,945.41 30,501,1a
Cost of materia8 .onsumed 1,003.18 868.80 1,610.01
Employe beneiit5 expenr5 1,185,26 1,123.23 1,241.44 5,167.00
167.d) 386,52 265.85 1,?tt.99
Depreciation and amortBatlon exp€nse 1,060.09 1,048.56 915.17 3,960,15
75.96 29.45 (89.04)
3,084,t2 3,119,21 2,672.93 't't,76J.n
6,910.15 5,425.19 75,741.61
l------1fr17
1,055.77 1,t12.08 4,171.41
vll Profit belore te (v-vr) 't,671,24 1,055,72 1,112.08 4,721.5'l
Vlll lncome td exp€.$
Clrrcnt tax erpenE 4o7_97 219.11 285.67 1,0f2.82
(ii ) Tar penaining to earlier year I1.19
(iii) Defetred tax expense/(crcdt) 156.21) 145.49 41.54 -t42.47
Total tar expense (vrrD t3,1,30 127.21 1,r15.29
lX Profit lor the period/year (vll-vlll) 1,258.20 1,406,22
Othe. comprehe.rive in.ome
(a) lteft that wlll not be re.l.ssified subsequently to prolit or lo$
(l) iemeasurement gain/(1o$) ofnet defined benefit plan 19,02 11.9f 26.00 76.@
(ii) hcome td elf4t on above t4.781 (9.55) (6.t4) (19.15)
Othe. com
[Showing first 8,000 characters — download PDF for full document]